TransThera Sciences (Nanjing), Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TT-00420 (tinengotinib) NCT06057571 |
P2 | Active, not recruiting | Cholangiocarcinoma Metastatic | 50 | 2025-07-27 (+1 mo) |
| FIRST-308 NCT05948475 |
P3 | Active, not recruiting | Cholangiocarcinoma | 200 | 2026-12 (+7 mo) |
| Tinengotinib at the optimal dose combined with Fulvestrant NCT07498478 |
P2 | Recruiting | Breast Cancer | 94 | 2027-06-30 |
| tinengotinib 10 mg QD plus darolutamide NCT07871110 |
P2 | Recruiting | Prostate Cancer (CRPC) | 182 | 2028-12-31 |
| TT-01488 Tablets NCT07855016 |
P2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 188 | 2029-10-10 |
| TT-00420 (tinengotinib) NCT07328919 |
P3 | Not yet recruiting | Intrahepatic Cholangiocarcinoma (Icc); Advanced Cholangiocarcinoma | 138 | 2029-12-31 |